Publication date: Jul 17, 2024
To investigate the association between COVID-19 and Parkinson’s disease (PD) via a single-center study and a Mendelian randomization (MR) study. A questionnaire-based survey was conducted among PD patients at a single center from December 7, 2022, to March 10, 2023. Logistic regression analysis was performed to identify the infection-related risk factors. Subsequently, bidirectional two-sample Mendelian randomization was employed to explore the association between COVID-19 and PD. In the cross-sectional analysis, it was found that the prevalence of COVID-19 infection in PD patients was 65. 7%. Forty-eight (35. 3%) PD patients experienced exacerbation of motor symptoms following COVID-19 infection. Long PD disease duration (≥ 10 years) (OR: 3. 327, P = 0. 045) and long time since last vaccination (> 12 m) (OR: 4. 916, P = 0. 035) were identified as significant risk factors related to infection. The MR analysis results supported that PD increases the COVID-19 susceptibility (β = 0. 081, OR = 1. 084, P = 0. 006). However, the MR analysis showed that PD did not increases the COVID-19 severity and hospitalization, and no significant association of COVID-19 on PD was observed. The findings from this cross-sectional study suggest that individuals with PD may experience worsened motor symptoms following COVID-19 infection. Long disease duration (≥10 years) and long time since last vaccination (> 12 m) are identified as important risk factors for infection in these patients. Furthermore, our MR study provides evidence supporting an association between PD and COVID-19 susceptibility.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | Parkinson’s disease |
| disease | MESH | infection |
| disease | VO | time |
| disease | VO | vaccination |
| disease | IDO | susceptibility |
| disease | MESH | Long Covid |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | parkinsonism |
| disease | VO | effective |
| disease | VO | vaccine |
| drug | DRUGBANK | Methionine |
| disease | IDO | history |
| disease | IDO | process |
| disease | IDO | host |
| pathway | REACTOME | Release |
| disease | VO | protocol |
| disease | MESH | Pneumonia |
| disease | VO | population |
| disease | VO | USA |
| disease | MESH | posture |
| disease | MESH | sore throat |
| disease | VO | nose |
| disease | MESH | chest pain |
| disease | MESH | dyskinesia |
| disease | IDO | symptom |
| disease | VO | age |
| disease | VO | vaccinated |
| disease | VO | vaccination dose |
| disease | IDO | intervention |
| disease | VO | adenovirus vaccine |
| disease | MESH | causality |
| disease | MESH | inflammation |
| disease | MESH | contraindications |
| disease | MESH | morbidity |
| disease | VO | frequency |
| pathway | KEGG | Influenza A |
| disease | MESH | bacterial pneumonia |
| pathway | KEGG | Parkinson disease |